Medical Management of Tenosynovial Giant Cell Tumor.

IF 5 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-05-20 DOI:10.1007/s11912-025-01679-x

Emanuela Palmerini, Jonathan C Trent, Francis John Hornicek

{"title":"Medical Management of Tenosynovial Giant Cell Tumor.","authors":"Emanuela Palmerini, Jonathan C Trent, Francis John Hornicek","doi":"10.1007/s11912-025-01679-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: Diffuse tenosynovial giant cell tumor (D-TGCT) is a benign neoplasm with locally aggressive potential of the synovium, bursae, and tendon sheaths. This review summarizes the current treatment landscape for D-TGCT, with a focus on systemic therapies.Recent findings: Surgery is the primary treatment option for tenosynovial giant cell tumor (TGCT), but there is a high risk of recurrence and associated morbidity, particularly for patients with advanced D-TGCT. Systemic therapies targeting the colony-stimulating factor 1 receptor (CSF1R) have resulted in positive tumor response, improved function, and decreased symptoms. For an alternative to surgery, the CSF1R inhibitors pexidartinib and vimseltinib are approved in the United States for TGCT, and other CSF1R inhibitors are in clinical development. CSF1R inhibitors represent a significant evolution in therapeutic strategies for D-TGCT. The potential risks and benefits of available treatments should be carefully considered in collaboration with a bone tumor-experienced, multidisciplinary team to determine the best course of care. Increased D-TGCT awareness and support through patient advocacy groups have helped to reshape the patient journey.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01679-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Diffuse tenosynovial giant cell tumor (D-TGCT) is a benign neoplasm with locally aggressive potential of the synovium, bursae, and tendon sheaths. This review summarizes the current treatment landscape for D-TGCT, with a focus on systemic therapies.

Recent findings: Surgery is the primary treatment option for tenosynovial giant cell tumor (TGCT), but there is a high risk of recurrence and associated morbidity, particularly for patients with advanced D-TGCT. Systemic therapies targeting the colony-stimulating factor 1 receptor (CSF1R) have resulted in positive tumor response, improved function, and decreased symptoms. For an alternative to surgery, the CSF1R inhibitors pexidartinib and vimseltinib are approved in the United States for TGCT, and other CSF1R inhibitors are in clinical development. CSF1R inhibitors represent a significant evolution in therapeutic strategies for D-TGCT. The potential risks and benefits of available treatments should be carefully considered in collaboration with a bone tumor-experienced, multidisciplinary team to determine the best course of care. Increased D-TGCT awareness and support through patient advocacy groups have helped to reshape the patient journey.

查看原文本刊更多论文

腱鞘巨细胞瘤的医学处理。

综述目的：弥漫性腱鞘巨细胞瘤（D-TGCT）是一种具有局部侵袭滑膜、滑囊和肌腱鞘潜能的良性肿瘤。这篇综述总结了目前D-TGCT的治疗前景，重点是全身治疗。最近发现：手术是腱鞘巨细胞瘤（TGCT）的主要治疗选择，但存在很高的复发和相关发病率风险，特别是对于晚期D-TGCT患者。针对集落刺激因子1受体（CSF1R）的全身治疗已导致肿瘤反应阳性，功能改善，症状减轻。作为手术的替代方案，CSF1R抑制剂派西达替尼和维姆西替尼在美国被批准用于TGCT，其他CSF1R抑制剂正在临床开发中。CSF1R抑制剂代表了D-TGCT治疗策略的重大演变。现有治疗方法的潜在风险和益处应与有骨肿瘤经验的多学科团队合作仔细考虑，以确定最佳治疗方案。通过患者倡导团体提高对D-TGCT的认识和支持，帮助重塑了患者的旅程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.